STVN

Stevanato Group S.p.A.

$13.53

-1.46%

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services.

Source: Yahoo Finance
AI summary

Price & performance

1M-33.5%
3M-31.6%
YTD-34.5%
1Y-45.5%
52-week range—
Beta0.71
Full chart and returns against a benchmark

Q-Score

52/ 100

Quality against peers; 50 is the peer median.

Growth57
Risk55
Performance33
Valuation63
Profitability59
Leverage58
Sentiment44
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$1.4B+21.3%
Net income$164.3M+34.0%
Net margin11.8%+1.1 pts
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsMar 4, 2026
Filings, findings and the timeline

Revenue exposure

Europe Middle East and Africa58%
North America31%
Asia Pacific9%
Regions, segments, customers and suppliers

Valuation

STVNIndustryP/E22.5049.36P/S2.653.73EV/EBITDA17.4623.12P/B2.123.92PEG0.660.66
Dividend yield0.47%
Every valuation metric

Earnings

Nov 3next report, before the open
EPS estimate$0.18
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate